278 related articles for article (PubMed ID: 29991290)
1. Optical coherence tomography angiography in myopic choroidal neovascularization after intravitreal ranibizumab.
Cennamo G; Amoroso F; Schiemer S; Velotti N; Alfieri M; de Crecchio G
Eur J Ophthalmol; 2019 Mar; 29(2):239-243. PubMed ID: 29991290
[TBL] [Abstract][Full Text] [Related]
2. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography.
Giorno P; Iacono P; Scarinci F; Di Renzo A; Varano M; Parravano M
Ophthalmologica; 2020; 243(4):263-270. PubMed ID: 31838464
[TBL] [Abstract][Full Text] [Related]
3. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
4. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
Wu TT; Kung YH
Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
Ladaique M; Dirani A; Ambresin A
Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
[TBL] [Abstract][Full Text] [Related]
7. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
8. FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.
Onishi Y; Yokoi T; Kasahara K; Yoshida T; Nagaoka N; Shinohara K; Kaneko Y; Suga M; Uramoto K; Ohno-Tanaka A; Ohno-Matsui K
Retina; 2019 Jul; 39(7):1289-1298. PubMed ID: 29746414
[TBL] [Abstract][Full Text] [Related]
9. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography.
Iacono P; Giorno P; Varano M; Parravano M
Eur J Ophthalmol; 2021 Jan; 31(1):149-157. PubMed ID: 31619075
[TBL] [Abstract][Full Text] [Related]
10. Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia.
Pastore MR; Capuano V; Bruyère E; Miere A; Corbelli E; Querques L; Tognetto D; Bandello F; Querques G; Souied EH
Ophthalmologica; 2018; 239(2-3):133-142. PubMed ID: 29268267
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
12. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab.
Varano M; Tedeschi M; Oddone F; Perillo L; Coppè AM; Parravano M
Retina; 2010 Mar; 30(3):413-7. PubMed ID: 20010453
[TBL] [Abstract][Full Text] [Related]
13. Fundus Autofluorescence Changes After Ranibizumab Treatment for Subfoveal Choroidal Neovascularization Secondary to Pathologic Myopia.
Parodi MB; Iacono P; Sacconi R; Iuliano L; Bandello F
Am J Ophthalmol; 2015 Aug; 160(2):322-327.e2. PubMed ID: 25935099
[TBL] [Abstract][Full Text] [Related]
14. Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization.
Howaidy A; Eldaly ZH
Eur J Ophthalmol; 2021 Jan; 31(1):211-217. PubMed ID: 31690105
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia.
Wasiluk E; Wojnar M; Obuchowska I; Mariak Z
Int Ophthalmol; 2020 Apr; 40(4):833-839. PubMed ID: 31788714
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
[TBL] [Abstract][Full Text] [Related]
17. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
[TBL] [Abstract][Full Text] [Related]
18. Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab.
Cohen SY; Tabary S; El Ameen A; Mrejen S; Quentel G; Giocanti-Auregan A
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):485-493. PubMed ID: 30535969
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal aflibercept for myopic choroidal neovascularization.
Pece A; Milani P
Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2327-2332. PubMed ID: 27286893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
